Form 4: Traws Pharma CEO Exercises Pre-Funded Warrants, Acquires Common Stock

Werner Cautreels, CEO of Traws Pharma, exercised pre-funded warrants to acquire 96,348 shares of common stock at $0.01 per share.

Summary

• On February 18, 2025, Werner Cautreels, the CEO of Traws Pharma, exercised pre-funded warrants.
• This resulted in the acquisition of 96,348 shares of common stock.
• The exercise price was $0.01 per pre-funded warrant.
• Following the transaction, Cautreels directly owns 104,348 shares of Traws Pharma common stock.
• The pre-funded warrants were acquired as part of Class B Units, with each unit consisting of one pre-funded warrant and one Series A warrant, at a purchase price of $5.093 per Class B Unit.
• The pre-funded warrants became exercisable upon stockholder approval on February 17, 2025, and do not expire.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard transaction. The CEO exercising warrants is neither overwhelmingly positive nor negative on its own.

Positives

• The CEO's exercise of warrants could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. The exercise of warrants is a standard mechanism for executives to increase their ownership stake.

Stakeholder Impact

• The transaction increases the CEO's alignment with shareholder interests.

Key Dates

Keywords

Traws Pharma, Werner Cautreels, CEO, pre-funded warrants, common stock, beneficial ownership, Form 4, acquisition